Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the enrollment of the first patient in its HORIZON Phase 2 clinical trial evaluating TNX-102 SL 5.6 mg as a first-line monotherapy for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study is expected to enroll approximately 360 patients at about 30 U.S. sites and will assess changes in depression severity after six weeks of treatment, along with measures of sleep quality, anxiety and global clinical improvement.
The news is significant because MDD is one of the most prevalent mental health disorders worldwide, affecting an estimated 21 million U.S. adults annually. Current treatments often have limited efficacy or significant side effects, and many patients do not achieve remission. TNX-102 SL is designed to improve sleep quality, which the company believes plays an important role in MDD. The therapy is already approved by the FDA under the brand name TONMYA(TM) for the treatment of fibromyalgia in adults. Tonix said the therapy has previously shown signals for improving depressive symptoms and subjective sleep quality in earlier clinical studies.
The implications of this trial are broad. If successful, TNX-102 SL could offer a novel mechanism for treating depression by targeting sleep disturbances, a common but often overlooked symptom of MDD. This could provide a new option for patients who do not respond to standard antidepressants or who experience intolerable side effects. Additionally, the drug is being developed for several other indications, including post-traumatic stress disorder, Long COVID, alcohol use disorder and agitation in Alzheimer's disease, suggesting a platform potential beyond MDD.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
The HORIZON trial is a critical step for Tonix as it seeks to expand the label of TNX-102 SL. For investors and the pharmaceutical industry, a positive outcome could validate the company's approach and open a substantial market. For patients, it represents hope for a treatment that addresses both depressive symptoms and sleep quality, potentially improving overall quality of life. The full press release is available at https://nnw.fm/dORql. For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.
